# Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)

D. Bennabi, A. Yrondi, T. Charpeaud, J.-B. Genty, S. Destouches, S.

Lancrenon, N. Allaili, F. Bellivier, T. Bougerol, V. Camus, et al.

## ► To cite this version:

D. Bennabi, A. Yrondi, T. Charpeaud, J.-B. Genty, S. Destouches, et al. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental). BMC Psychiatry, 2019, 19 (1), pp.1-9. 10.1186/s12888-019-2025-7. hal-02524126

HAL Id: hal-02524126

https://univ-tours.hal.science/hal-02524126

Submitted on 30 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_1.png" /></figure>
RESEARCH ARTICLE

Open Access

<figure><img src="image_2.png" /></figure>

CrossMark

# Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)

D. Bennabi<fnref n="1" />*, A. Yrondi², T. Charpeaud³, J.-B. Genty⁴, S. Destouches⁴, S. Lancrenon⁴, N. Allaili⁵, F. Bellivier⁵, T. Bougerol⁶, V. Camus⁷, O. Doumy⁸, J.-M. Dorey⁹,¹⁰,¹¹, F. Haesebaert¹², J. Holtzmann⁶, C. Lançon¹³, M. Lefebvre¹², F. Moliere¹⁴, I. Nieto⁵, C. Rabu¹⁵, R. Richieri¹³, L. Schmitt², F. Stephan¹⁶, G. Vaiva¹⁷, M. Walter¹⁶, M. Leboyer¹⁵, W. El-Hage⁷, B. Aouizerate⁸, E. Haffen<fnref n="1" />, P.-M. Llorca³ and P. Courtet¹⁴

**Abstract**

**Background:** Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking.

**Method:** The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriateness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments.

**Results:** The expert guidelines combine scientific evidence and expert clinician's opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression.

**Conclusion:** These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.

**Keywords:** Major depressive disorder, Anxiety disorders, Substance use disorders, Elderly, Pharmacotherapy

<footnote>* Correspondence: djamila.bennabi@univ-fcomte.fr</footnote>

<footnote n="1">¹Service de Psychiatrie clinique, Centre Expert Dépression Résistante
FondaMental, Centre Investigation Clinique 1431-INSERM, EA 481
Neurosciences, Université de Bourgogne Franche Comté, 25030 Besançon,
France</footnote>

<footnote>Full list of author information is available at the end of the article</footnote>
## Background

Major depressive disorder (MDD) is becoming a major challenge for public health and medical practice, directly accounting for 4.4% of disease burden worldwide [1]. MDD is one of the most frequently recurrent psychiatric disorders, associated with a high risk of chronicity. Depressive disorders can occur comorbidly with nearly every other form of psychopathology in an unsystematic way, leading to greater symptom severity, disability, more suicides and poorer treatment response [2, 3]. Studies of adults patients with MDD reveal high prevalence rates of current social anxiety disorder (25,6%), panic disorder (11,1%), generalized anxiety disorder (20,8%), obsessive-compulsive disorder (13,4%), post-traumatic stress disorder (18,8%), alcohol abuse/ dependance (11,9%) and drug abuse/dependance (7,3%) [4]. Despite advances in patient's management, response rates to first-line antidepressants are moderate (40–60%), and remission is achieved in a minority of patients. For instance, in the STARD study, the remission rate reaches up to 60% after four subsequent trials although the probability of remission drops significantly after the failure of two consecutive antidepressants [5, 6]. Given the public health consequences of inadequately treated depression, guidance regarding treatment selection for MDD could have major impact. A number of guidelines have already been developed by professional societies with the aim to standardize treatments and to orientate everyday clinical practice towards evidence base. They integrate recommendations draws up after a critical analysis of available data, which are selected and ranked according to their level of evidence. Each compound is assigned a Level or Category of evidence (CE), which basically describes the level of efficacy. Subsequently, different Clinical recommendations or Recommendation Grades (RG) are implemented, which integrate additional clinical aspects of safety, tolerability and effectiveness. Despite a rigorous approach at both scientific and methodological levels, Evidence-Based Guidelines (EBG) can be limited in their usefulness and applicability by a number of different factors, including the availability of high-quality research evidence, the generalisability of research findings and the uniqueness of individuals with depression. One of the main obstacle stems from the use of restrictive criteria in most high-level Randomized Controlled Trials (RCT) excluding psychiatric comorbidities and elderly patients. Although the issue of comorbidity is recognized by EBGs, few specific recommendations are provided regarding acute treatment with antidepressant drugs, practical issues in prescribing and management or next-step treatment in those complex clinical situations. In these cases, the Formal Consensus method,

based on the practical experience of a panel of experts, offer support strategies and appears to be particularly relevant. This method has been previously used by the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) and the fondation FondaMental (www.fondation-fondamental.org) to make recommendations for pharmacological and psychological strategies in depression (Bennabi et al., submitted).

The French National Health agency recommends the Formal Consensus method when the following conditions are met:

- No or insufficient level of evidence addressing the question.

- Possibility to decline the topic in easily identifiable clinical situations.

- Need to identify and select the strategies deemed appropriate by an independent panel from amongst several alternative options.

The AFPBN and the fondation FondaMental have developed a series of recommendations expected to provide a clear guidance regarding treatment options for specific populations/situations such as psychiatric comorbid disorders (ie anxiety disorders, personality disorders and addictions) and elderly, complementary to the Formal Consensus Guidelines for treating adults with treatment-resistant depression (TRD). We provide a synthesis of the deliberations of a panel of experts highly specialized in the field of unipolar depression, thereby enabling to establish recommendations for the pharmacologic treatment of MDD in elderly patients, patients with comorbid anxiety disorders, personality disorders or substance use disorders.

## Methods

The methodology has been previously described (see recommendations for treating TRD (Bennabi et al., submitted)). Recommendations were determined using the RAND/UCLA Appropriateness Method. This method combines scientific evidence and expert opinion to assess the appropriateness of medical procedures. It involves the following steps: (I) comprehensive review and analysis of the literature with regard to the research question conducted by a scientific committee (II) elaboration of the questionnaire to collect experts' opinions for several highly detailed and illustrative clinical presentations; (III) scoring of the questionnaires; (IV) analysis of the experts' opinions and drafting of the final report; (V) Peer-review phase; (VI) diffusion of the recommendations. This consensus survey of expert opinion on the
pharmacologic treatment of MDD in specific populations/situations (elderly and comorbidities with anxiety disorders, personality disorders or addictions) was undertaken by the French Association of Biological Psychiatry and fondation FondaMental. The written survey was completed by 36 psychiatrist experts in the field of major depression and its treatments.

The scoring of the questionnaires was made using a modified version of the RAND 9-point scale for rating the appropriateness of medical decisions. Each expert answered each question with a graduated scale from 0 to 9 derived from a variation of the “Nominal Group” method, developed by the Rand Corporation and the University of California in the USA (“RAND/UCLA appropriateness rating method”), 0 meaning a “total disagreement” or “a formal contraindication” and 9 indicating a “total agreement” or “a formal indication”. This process is meant to detect agreement among experts without trying to promote consensus and potentially reduce the real differences of clinical opinion. This method has been previously used by the AFBPN to make recommendations for the use and management of long-acting injectable antipsychotics in bipolar disorder and for the management of TRD [7].

## Recommendations

### Comorbid anxiety disorders

*During the first episode of MDD with comorbid anxiety disorder, it is recommended in first intention*

- The concurrent treatment of both disorders

- The disease management by the same therapist as much as possible, which includes systematically a cognitive behavioural therapy along with a closer follow-up.

Strategies recommended for the pharmacological treatment of MDD depending on the comorbid anxiety disorder are presented in Table 1.

### Comorbid substance use disorders

*During the first episode of MDD with comorbid substance use disorders, it is recommended in first intention*

- The recourse to full time hospitalization or

- The close monitoring in consultation (at least weekly),

- The electrocardiogram before treatment administration,

- The initiation of a substitution treatment in opioid drug dependence

<table><caption>**Table 1** Therapeutic strategies depending on comorbid anxiety disorder</caption><thead><tr><th>Comorbidity</th><th>First intention</th><th>Second intention</th><th>Contra-indications</th></tr></thead><tbody><tr><td rowspan="2">Obsessive-compulsive disorders</td><td>- SSRI</td><td>- Imipraminic</td><td>- Tianeptine</td></tr><tr><td>- SNRI</td><td>- α2 Antagonist</td><td>- Irreversible non selective MAOI</td></tr><tr><td></td><td>- Psychotherapy in combination</td><td>- Association of two ATDs from different pharmacological class</td><td>- First-generation antipsychotic</td></tr><tr><td></td><td></td><td>- Potentiation with AAP</td><td>- Anticonvulsant</td></tr><tr><td>Panic disorders</td><td></td><td>- Imipraminic</td><td>- Association of ATDs</td></tr><tr><td>Social anxiety</td><td></td><td>- α2 Antagonist</td><td>- Anticonvulsant</td></tr><tr><td>Generalised anxiety disorder</td><td></td><td></td><td>- First-generation antipsychotic</td></tr><tr><td>Post-traumatic stress disorder</td><td></td><td></td><td>- AAP</td></tr></tbody></table>

AAP Atypical antipsychotic, ATD Antidepressant, MAOI monoamine oxidase inhibitor, SSRI Selective serotonin reuptake inhibitors; SNRI: Dual serotonin and norepinephrine reuptake inhibitors

More specifically, in case of severe alcohol addiction, the following procedure must also be considered in first intention, including:

- The close biological monitoring (complete blood count, blood electrolyte, liver and renal functions),

- The treatment of physical withdrawal syndrome,

- The prescription of antidepressant treatment after reassessment of mood, once appropriate care for physical withdrawal syndrome is over.

Strategies recommended for the treatment of MDD depending on the comorbid substance use disorder are presented in Table 2.

### Personality disorders

*During the first episode of MDD with comorbid personality disorder, it is recommended*

- The use of SSRI or SNRI in monotherapy or in combination with a psychotherapy in first intention

- The prescription of imipraminic antidepressant or α2 antagonist in second intention

Second-generation Antipsychotic or Acid valproic derivatives in association with the ongoing antidepressant treatment could possibly be considered in second intention.

Brain stimulation techniques are fully non-recommended.
<table><caption>**Table 2** Therapeutic strategies depending on comorbid substance use disorders</caption><thead><tr><th>Comorbidity</th><th>First intention</th><th>Second intention</th><th>Contra-indications</th></tr></thead><tbody><tr><td>Severe substance use disorders<br>(except alcohol and nicotine)</td><td>- SSRI<br>- SNRI<br>- a2 antagonist<br>- Concurrent treatment of MDD and addiction<br>- Disease management involving a team specialised<br>in addictology, psychoeducational groups or a<br>psychotherapy focusing on addictive relapse prevention</td><td>- Imipraminic<br>- Agomelatine</td><td>- Tianeptine<br>- Irreversible non selective MAOI<br>- First-generation antipsychotic<br>- Association of ATD<br>- Anticonvulsant</td></tr><tr><td>Severe comorbid alcohol addiction</td><td>- SSRI<br>- SNRI<br>- a2 antagonist<br>- Structured Psychotherapy</td><td>- Disulfiram<br>- Tianeptine<br>- Bupropion<br>- Irreversible non selective MAOI<br>- Treatment of MDD alone</td><td></td></tr><tr><td>Active smoking</td><td>- SSRI<br>- SNRI<br>- a2 antagonist<br>- Structured Psychotherapy<br>- Concurrent treatment of MDD and smoking-cessation</td><td>- Imipraminic<br>- Agomelatine</td><td>- Irreversible non selective MAOI<br>- Tianeptine</td></tr></tbody></table>

AAP Atypical antipsychotic, ATD Antidepressant, MAOI monoamine oxidase inhibitor, MDD Major depressive disorder, SSRI Selective serotonin reuptake inhibitors, SNRI Dual serotonin and norepinephrine reuptake inhibitors

## Geriatric depressive disorder

During an episode of MDD in adults over 65 years of age, it is recommended in first intention to perform a physical examination and ordering laboratory investigations to identify any medical problems that could contribute to or mimic depressive symptoms

- A clinical examination

- A Biological check-up (ie Complete blood count, blood electrolyte, liver and renal functions, Thyroid-Stimulating Hormon)

- An Electrocardiogram

- A Mini Mental State Examination

- The Assessment of the severity of patients' clinical condition with clinician-rated and self-rated scales.

According to the experts' panel, MRI may be considered in those with in late or very late onset first episode depression, those having associated neurological signs and those experiencing treatment resistant depression.

Anxiolytic treatment is not recommended in association with the current antidepressant. If used, hydroxyzine as well as benzodiazepines with short half-life must be preferred (for instance oxazepam).

Therapeutic strategies for MDD in patients over 65 years of age depending on clinical features of the episode are presented in Table 3.

## Discussion

The main interest of the current expert guideline is to provide insights into the treatment practices of clinician experts across a number of common and complex clinical situations, with a particular attention paid to first and second-line strategies in patients with comorbid

depressive disorders and anxiety, substance abuse or personality disorders and in elderly patients. Although the issue of comorbidity is recognized by EBGs, few specific recommendations are generated to aid clinician decision making at different steps of treatment, especially following the failure of the first-line strategy. This probably reflects the paucity of extant primary studies addressing these critical clinical questions. In such instances, CBG methodologies help to fill the gap between empirical literature and clinical practice and to reduce disparities in care. While some differences between EBG and CBG can be mentioned, the combination of these two approaches contributes to significantly facilitate and guide the treatment decision and choice in routine clinical practice.

## Recommendations for comorbid depression and anxiety disorders

The treatment of comorbid anxiety and depression requires specific psychopharmacological adjustments as compared to treating either condition alone. EBGs encouraged to screen and systematically monitor for comorbid anxious conditions in all individuals with mood disorders, although it is often unclear whether a sequential or a concurrent approach should be preferred for their management [8–11]. The UK National Institute for Health and Clinical Excellence (NICE) guideline directly acknowledged this shortcoming, and proposed a sequential approach that targets “the primary disorder” first (ie the one that is more severe and in which it is more likely that treatment will improve overall functioning) [12]. Experts’ support for using Selective serotonin reuptake inhibitors (SSRI) or Dual serotonin and norepinephrine reuptake inhibitors (SNRI) as first-line treatment in
<table><caption>**Table 3** Therapeutic strategies in geriatric depression</caption><thead><tr><th>Clinical features</th><th>First intention</th><th>Second intention</th><th>Contra-indications</th></tr></thead><tbody><tr><td>Mild to moderate intensity</td><td>- SSRI<br>- α2 antagonist</td><td>- SNRI<br>- Agomelatine</td><td>- Irreversible MAOI<br>- Bupropion<br>- Association with an ATD from the same pharmacological class<br>- Anticonvulsant<br>- ECT</td></tr><tr><td>Moderate to severe intensity</td><td>- SSRI<br>- SNRI<br>- α2 antagonist</td><td>- Imipraminic</td><td>- Bupropion<br>- Association with an ATD from the same pharmacological class<br>- Anticonvulsant</td></tr><tr><td>Severe cognitive impairments</td><td>- SSRI<br>- SNRI</td><td>- α2-antagonist<br>- Agomelatine</td><td>- First generation antipsychotic</td></tr><tr><td>Severe psychomotor agitation</td><td>- SSRI<br>- α2 antagonist</td><td>- SNRI<br>- Potentiation with AAP</td><td>- Bupropion<br>- Tianeptine<br>- Irreversible MAOI<br>- Association with an ATD from the same pharmacological class</td></tr><tr><td>Severe psychomotor retardation</td><td>- SSRI<br>- SNRI</td><td>- α2-antagonist<br>- Imipraminic<br>- ECT in association</td><td>- Tianeptine<br>- Bupropion<br>- Association with an ATD from the same pharmacological class<br>- First generation antipsychotic</td></tr><tr><td>Severe sleep disorders</td><td>- SSRI<br>- α2 antagonist</td><td>- SNRI<br>- Agomelatine</td><td>- Tianeptine<br>- Irreversible MAOI<br>- Bupropion<br>- Association with an ATD from the same pharmacological class</td></tr><tr><td>Severe anhedonia</td><td>- SSRI<br>- SNRI</td><td>- α2-antagonist<br>- Imipraminic<br>- Agomelatine</td><td>- Association with an ATD from the same pharmacological class<br>- Anticonvulsant<br>- First generation antipsychotic</td></tr><tr><td>Psychotic symptoms</td><td>- SNRI<br>- Potentiation with AAP</td><td>- SSRI<br>- α2-antagonist<br>- Imipraminic<br>- ECT in association</td><td>- Tianeptine<br>- Irreversible MAOI<br>- Bupropion<br>- Association with an ATD from the same pharmacological class</td></tr><tr><td>High suicidal risk</td><td>- SSRI<br>- SNRI</td><td>- α2-antagonist<br>- Imipraminic<br>- ECT in association<br>- Potentiation with AAP</td><td>- Tianeptine<br>- Bupropion<br>- Association with an ATD from the same pharmacological class<br>- First generation antipsychotic</td></tr></tbody></table>

AAP Atypical antipsychotic, ATD Antidepressant, ECT Electroconvulsive therapy, MAOI monoamine oxidase inhibitor, SSRI Selective serotonin reuptake inhibitors, SNRI Dual serotonin and norepinephrine reuptake inhibitors

depression comorbid with a spectrum of anxiety disorders is consistent with an extensive literature documenting safety and efficacy of these agents for both coexisting disorders [13]. Some but not all research have suggested that dual action drugs such as SNRIs might be superior to SSRIs for treating simultaneously both disorders [14]. Second-intention pharmacological approaches include trials of alternative medications as monotherapies with an Imipraminic or an α2 antagonist. Tricyclic antidepressants (TCA) cover both depression and certain anxiety disorders including GAD or PD, but are less commonly used due to tolerability issues [15–17]. Clobipramine appeared to be more effective than placebo in the treatment of Obsessive-compulsive disorders (OCD), and is recommended by the World Federation

of Societies of Biological Psychiatry (WFSBP) and the American Psychiatric association (APA) in this indication [8, 9]. Alpha2 antagonists are also considered by the experts as second-line treatment, consistent with findings from randomized trials demonstrating mirtazapine's anxiolytic and overall efficacy in MDD with prominent anxiety symptoms [18]. Notably, mirtazapine might be especially effective in patients with MDD and comorbid GAD, SAD or PTSD [19–21]. For the pharmacological management of MDD with comorbid OCD, the expert's panel also favoured using adjunctive AAP or an association of two ATDs from different pharmacological class in second line. These special caution on OCD probably reflect difficulties in their management, as OCD have a reduced overall pharmacological response to ATD
compared to GAD, panic disorder, PTSD and SAD [22]. However, there is currently no convincing evidence for the efficacy of a combination of antidepressants in this specific indication, except for the combination of SSRIs with clomipramine [23, 24]. Regarding add-on strategies, risperidone is among the most recommended treatment options for augmenting SSRIs in OCD while quetiapine and aripiprazole have both demonstrated efficacy as adjuncts for MDD with comorbid anxiety disorders in one RCT and three open label trial [25–29].

The expert recommended a concomitant use of ATD and psychotherapy (PT) in first intention, while some EBGs for the treatment of depression and comorbid anxiety disorders, for example, that of the WFSBP, the APA, the Canadian Network for Mood and Anxiety Treatments (CANMAT) propose to consider PT in combination or as an alternative to pharmacotherapy in case of non- or partial response, and frequently cited Cognitive Behavioral Therapy and Interpersonal Therapy [8–10]. To date, it has not been clearly established whether combined treatments with psychotherapy and antidepressant medication lead to higher effects than the sum of the two treatments alone. Moreover, from a clinical point of view, the lack of available psychological treatments limits their use. In such instances, self-guided internet-based cognitive behavioral therapy could be a promising alternative due to its potential to increase access and availability of evidence-based therapy [30].

## Recommendations for comorbid depression and substance abuse/dependence

Experts' support for treating co-occurring depression when it persists after at least a brief period of abstinence from substance use is consistent with several EBGs, even though most of them do not identified a preferred pharmacological option [8–11]. SSRI and SNRI are considered as an attractive first-line treatment among substance-dependent patients, probably because of their safety profile, and minimal sedating effects. If an SSRI or SNRI trial fails, consideration should be given to an imipraminic agent or agomelatine. A 2004 meta-analysis by Nunes and Levin found evidence for a modest beneficial effect of ATD on mood symptoms in depressed subjects with SUDs [31]. However, it should be notice that safety concerns regarding TCA have impeded both research and clinical use of these drugs in depressed patients with comorbid SUDs [32].

Regarding treatment options for patients with comorbid alcohol dependence, beside SSRI and SNRI, the use of an α2 antagonist in first line reflects the current empirical literature providing some evidence of efficacy for mirtazapine to elevate mood in persons with co-occurring MDD/ alcohol use disorders, without

effectiveness for decreasing the level of alcohol ingestion [33]. Some guidelines, for exemple that of the CANMAT provides a particular sequence of interventions with first, second- and third-choice therapies, with several options within each intervention step [10]. In the specific case of smoking cessation, only the APA provided specific recommendations and proposed to consider bupropion or nortriptyline based on evidences suggesting that these agents provides an additional long-term benefit [9]. Experts' recommendations were limited to SSRI, SNRI and α2 antagonists in first intention, however it should be noted that bupropion has not yet received approval for MDD in France.

Globally, it should be critically considered that data are sparse, in part because individuals with SUDs are traditionally excluded from medication trials for MDD and trials in dependant patients suffers from several methodological limits, including short trials lengths, inadequate ATD doses, and selection of patients with cross-sectional measures of depressive symptoms.

## Recommendations for comorbid depression and personality disorders

Key-issues identified with regards to the overlap of major depression and personality disorders include whether personality traits or disorders modify treatment responsiveness and outcome of mood disorder [34]. Due to the scarcity of original treatment studies specifically focused on these conditions, most EBGs provide general guidance but do not include hierarchical levels of evidence for pharmacotherapy. The CANMAT emphasised that patients with mood disorders and concurrent personality disorders should be treated with a combination of diagnostic-specific pharmacotherapy and PT, but without specified if a concurrent or a sequential approach should be favoured, while the APA adviced targeting the depressive disorder [9, 10]. The recommendations from the expert's panel, and the APA are consistent, with SSRI as a first-line strategy, alone or in combination with PT [9]. The advice on pharmacotherapy was also similar on the use of low-dose antipsychotics and some antiepileptic medications for treating impulsivity and loss of control.

## Recommendations for geriatric depressive disorders

Most of the European and North American EBGs have no special chapter or separate section for geriatric depression. General principles for treating older adults are similar to those described for younger adults, with special caution for adverse drug reactions, potential drug interactions and somatic comorbidities [12]. Moreover, EBGs acknowledged that older patients would usually require lower doses of medication, due to the association of aging with reductions in renal clearance and volume
of distribution and concomitant medications. The formalized consensus of our experts' panel provides recommendations on older adults with depression based on several dimensional features. Overall, experts' support for using SSRI or SNRI as first-line treatment is congruent with the CANMAT, the APA and the WFSBP guidelines, documenting both safety and efficacy of these strategies [8–10, 35]. The CANMAT provides a detailed stepped approach with a first, a second and a third-line intervention [10]. The use of α2 antagonists in MDD with severe sleep disorders or psychomotor agitation adviced by the experts probably results from its sedative properties and its more rapid onset of action. This assumption in mainly based on the study by Schatzberg and colleagues showing that mirtazapine exhibit more notable antidepressant effects than the standard SSRI paroxetine, with greater reductions in anxiety levels, somatic symptoms and sleep disturbances in 255 elderly depressed patients [36]. Despite two RCT and one naturalistic trial supporting the use of bupropion in older adults with MDD, and while both the Canadian and the US guidelines recommend its use as first and second-line treatment, the experts we surveyed do not advocated its use, due to the absence of approval for the treatment of MDD in France [9, 10, 37].

The formal consensus method is used to specify a prescription framework for specific populations or clinical situations for which evidence are scarce or debated, which is the case in major depressive disorder with psychiatric comorbid disorders. Indeed, in those situations, empirical literature is lacking for specific iterative medications. However, a limited number of comorbid conditions were included in our study. Comorbid anxiety and substance use disorders are frequently associated with MDD, but there is also substantial overlap with other medical and psychiatric comorbidities (e.g. attention deficit hyperactivity disorder) for whom a thorough investigation is needed. Second, expert's prescribing choice may be influenced by perceived therapeutic actions or perceived risk of adverse drug events, or both leading to provide recommendations even when little evidence of superior efficacy of one agent over another exists in the literature [38, 39].

## Conclusion

Within the limits of expert opinion and with the expectation that future research data will take precedence, these guidelines provide direction for addressing common clinical dilemmas that arise in the pharmacological treatment of MDD with comorbid conditions.

Although standard guidelines contribute to facilitate and guide the treatment decision and choice for the clinicians, they cannot take into account the overall complexities involved in the care of each individual

patient or substitute professional knowledge and clinical judgement. Importantly, additional researches concerning the temporal onset of the disorders, similarities and differences in neurobiological substrates, heritability, and environmental stressors associated with each disorder are needed. Identification of shared etiological factors that underlies the comorbidity in depressive disorders may contribute to the development of better interventions that target not only MDD but also other major sources of psychiatric morbidity. Adequately powered, well-controlled studies are further needed to show the effectiveness of treatments for depression with comorbid under conditions of routine clinical practice.

## Abbreviations

AAP: Atypical Antipsychotic; AFBPN: Association for Biological Psychiatry and Neuropsychopharmacology; EBG: Evidence-based guidelines;

ECT: Electroconvulsive therapy; GAD: Generalised anxiety disorder;

MAO: Monoamine oxidase inhibitors; MDD: Major depressive disorder;

OCD: Obsessive-compulsive disorders; PD: Panic disorders; PTSD: Post-traumatic stress disorder; RCT: Randomized controlled trials; SA: Social anxiety; SNRI: Dual serotonin and norepinephrine reuptake inhibitors;

SSRI: Selective serotonin reuptake inhibitors; TCA: Tricyclic antidepressant; TRD: Treatment-resistant depression

## Acknowledgements

The authors are grateful to the experts who completed the survey which had allowed the development of these recommendations. The authors also thank the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN), the fondation FondaMental, the expert centres for TRD, the SYLIA-STAT society, Mrs. Maria CHOVET, Mrs. Mihaela HONCIUC, and Mrs. Claire NOBILET-SEGUIN.

## Funding

The authors received no specific funding for this work.

## Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions

DB, AY, TC, J-BG, SD, SL, NA, FB, TB, VC, OD, J-MD, FH, JH, CL, MYL, FM, IN, CR, RR, LS, FS, GV, MW, ML, WE, BA, EH, PML, PC contributed substantially to writing of the article or revising it critically for important intellectual content, and to final approval of the version to be submitted.

## Ethics approval and consent to participate

Written informed consents were obtained from participating medical experts.

## Consent for publication

Not Applicable.

## Competing interests

No financial support was received for this study and there are no potential conflicts of interest to declare. Regarding financial support unrelated to the present article, we disclose that NA has benefited from financial support for conferences and has been scientific responsible and experimenter for preclinical studies from Servier laboratories. BA has perceived honoraria to communicate at conferences from Laboratories AstraZeneca, Lundbeck and Janssen. VC has benefited from honoraria and financial support for conferences from Laboratories Otsuka, Novartis, Lundbeck, Servier, Janssen and has been experimenter for studies from Janssen and Lilly.TC has benefited from honoraria and financial support for conferences from Laboratories AstraZeneca, Janssen and Lundbeck and has been experimenter for studies from Janssen. PC has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Servier and Janssen. OD has
benefited from honoraria and financial support for conferences from Lilly, AstraZeneca, Servier, Lundbeck and Janssen. J-MD has benefited from honoraria for conferences from Lundbeck. WE has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Lundbeck, Janssen, and Otsuka. FH has benefited from financial support for conferences, grant from BMS and AstraZeneca, training grant from Servier and a research grant from « Fonds de Recherche du Québec - Nature et Technologie (#200123) » and has been experimenter for studies from EH has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from AstraZeneca, BMS, Euthérapie Servier, Janssen, Livanova, Lundbeck, Otsuka and has been experimenter for studies from Janssen. JH has benefited from honoraria and financial support for conferences from Lundbeck, Servier has been experimenter for studies from Janssen. CL has benefited from honoraria and financial support for training action from Lundbeck. P-ML has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Janssen, EISAI, Lundbeck, Otsuka, Allergan. FM has benefited from honoraria for conferences from Lundbeck, Otsuka. GV has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Janssen and Otsuka. AY has benefited from honoraria and financial support for conferences from Lundbeck, Janssen, AstraZeneca; for participation in experts groups from Lundbeck and has participated in research studies from Lundbeck.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

¹Service de Psychiatrie clinique, Centre Expert Dépression Résistante FondaMental, Centre Investigation Clinique 1431-INSERM, EA 481 Neurosciences, Université de Bourgogne Franche Comté, 25030 Besançon, France. ²Service de Psychiatrie et de Psychologie Médicale de l'adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Toulouse, Hospital Purpan, ToNIC, Toulouse Neurolmaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France. ³Service de Psychiatrie de l'adulte B, Centre Expert Dépression Résistante FondaMental, CHU de Clermont-Ferrand, Clermont-Ferrand, France. ⁴SYLIA-STAT, 10, boulevard du Maréchal-Joffre, 92340 Bourg-la-Reine, France. ⁵Service de Psychiatrie adulte, Centre Expert Dépression Résistante FondaMental, Hôpital Fernand-Widal, Paris, France. ⁶Service de Psychiatrie de l'adulte, CS 10217, Centre Expert Dépression Résistante FondaMental, CHU de Grenoble, Hôpital Nord, Grenoble, France. ⁷Clinique Psychiatrique Universitaire, Centre Expert Dépression Résistante FondaMental, CHRU de Tours, Université de Tours, Inserm U1253 imaging and Brain: iBrain, Tours, France. ⁸Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, UMR INRA 1286, NutriNeuro, Université de Bordeaux, Bordeaux, France. ⁹Old Age Psychiatry Unit, pôle EST, Centre Hospitalier le Vinatier, Bron, France. ¹⁰Brain Dynamics and Cognition, Lyon Neuroscience Research Center, InserM U1028, CNRS UMR 5292, Lyon, France. ¹¹Geriatrics Unit, CM2R, Hospices civils de Lyon, Hôpital des Charpennes, Villeurbanne, France. ¹²Service universitaire des pathologies psychiatriques résistantes, Centre expert FondaMental, PSYR2 Team, Lyon Neuroscience Research Center, InserM U1028, CNRS UMR5292, Centre Hospitalier Le Vinatier, University Lyon 1, Bron, France. ¹³Pôle Psychiatrie, Centre Expert Dépression Résistante FondaMental, CHU La Conception, Marseille, France. ¹⁴Département des Urgences et Post-Urgences Psychiatriques, Centre Expert Dépression Résistante FondaMental, CHU Montpellier, Univ Montpellier, Montpellier, France. ¹⁵DHU PePSY, Pole de psychiatrie et d'addictologie des Hôpitaux Universitaires Henri Mondor, Université Paris Est Créteil, Créteil, France. ¹⁶Service hospitalo-universitaire de psychiatrie d'adultes et de psychiatrie de liaison - secteur 1, Centre Expert Dépression Résistante Fondamental, CHRU Brest, hôpital de Bohars, Bohars, France. ¹⁷Service de Psychiatrie adulte, Centre Expert Dépression Résistante FondaMental, CHU de Lille, Hôpital Fontan 1, Lille, France.

Received: 7 August 2018 Accepted: 11 January 2019

Published online: 30 January 2019

**References**

1. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21

regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197-223.

2. Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, et al. Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand. 2005;112(6):425-33.

3. Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord. 2012;139(2):172-80.

4. Rush AJ, Zimmerman M, Wisniewski SR, Fava M, Hollon SD, Warden D, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord. 2005;87(1):43-55.

5. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11):1905-17.

6. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.

7. Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca P-M. French Society for Biological Psychiatry and Neuropsychopharmacology task force: formal consensus for the prescription of depot antipsychotics. Encéphale. 2013;39(Suppl 4):189-203.

8. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334-85.

9. Gelenberg. Practice guideline for the treatment of patients with major depressive disorder. In: American psychiatric association; 2010.

10. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatr. 2016;61(9):540-60.

11. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol (Oxford). 2015;29(5): 459-525.

12. National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults (Updated Edition), National Institute for Health and Clinical Excellence: Guidance. Leicester (UK): British Psychological Society; 2010.

13. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry. 2005; 66(Suppl 8):22-9.

14. Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother. 2007;41(10):1583-92.

15. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry. 1993;54(Suppl):20-3.

16. Wittchen H-U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-71.

17. Mavissakalian M. Antidepressants in the treatment of agoraphobia and obsessive-compulsive disorder. Compr Psychiatry. 1983;24(3):278-84.

18. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry. 1998;59(3): 123-7.

19. Goodnick PJ, Puig A, DeVane CL, Freund BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry. 1999;60(7):446-8.

20. Muehbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(6):580-3.

21. Davidson JRT. Treatment of posttraumatic stress disorder: the impact of paroxetine. Psychopharmacol Bull. 2003;37(Suppl 1):76-88.

22. Sugarman MA, Kirsch I, Huppert JD. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis. J Affect Disord. 2017;218:217-26.

23. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder - Eur Psychiatry. 1999;14(2):101-6.

24. Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or
clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011;31(6):763-8.

25. Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19(2):121-6.

26. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86(1):99-104.

27. Yargic LI, Corapcioglu A, Kocabasoglu N, Erdogan A, Koroglu G, Yilmaz D. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatry Clin Pract. 2004;8(4):205-11.

28. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487-94.

29. Coplan JD, Aaronson CJ, Panthangi V, Kim Y. Treating comorbid anxiety and depression: psychosocial and pharmacological approaches. World J Psychiatry. 2015;5(4):366-78.

30. Karyotaki E, Riper H, Cuijpers P. Internet-based self-help interventions for depression in routine care: reply. JAMA Psychiatry. 2017;74(8):853.

31. Nunes EV, Levin FR. Treatment of co-occurring depression and substance dependence: using meta-analysis to guide clinical recommendations. Psychiatr Ann. 2008;38(11):nihpa128505.

32. Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci. 2015;17(2):181-90.

33. Cornelius JR, Chung TA, Douaihy AB, Kirisci L, Glance J, Kmiec J, et al. A review of the literature of mirtazapine in co-occurring depression and an alcohol use disorder. J Addict Behav Ther Rehabil. 2016;5(4).

34. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry. 2006; 188:13-20.

35. Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014;30(3):517-34.

36. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Mirtazapine vs. paroxetine study group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10(5):541-50.

37. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016;6(2):99-144.

38. Fernandes AC, Chandran D, Khondoker M, Dewey M, Shetty H, Dutta R, et al. Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting. BMJ Open. 2018;8(9):e022170.

39. Jilani TN, Saadabadi A. Mirtazapine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 [cited 2018 Nov 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBKS19059/.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

<figure><img src="image_3.png" /></figure>